Ghyslain Mombo-Ngoma, MD, PhD, led a study in Gabon in which researchers gave a single-dose treatment combining an ...

Conservation biologist Brian Gratwicke searches with his team for frogs in Altos de Campana National Park in Panama. Nate ...

A new drug called GanLum has shown over 97% success in treating malaria, offering fresh hope as resistance to standard ...

In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...

Researchers have built a 3D human blood-brain barrier in the lab and discovered a key role of brain pericytes in cerebral malaria disease Cerebral malaria is a deadly complication of Plasmodium ...

Roche is forging ahead with plans to seek approval for an eye disease drug candidate despite missing the primary endpoint in one of its phase 3 trials. The Swiss drugmaker ran two identical studies, ...

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and ...

Prediction of Treatment Efficacy in Locally Advanced Rectal Cancer Using a Clinical and Magnetic Resonance Imaging–Based Radiomics-Immunological Model for Total Neoadjuvant Therapy Fifty patients were ...

Heart disease continues to stand as the No. 1 cause of death in the United States. Coronary heart disease, the most common type of heart disease in the U.S., was responsible for the deaths of nearly ...

Glassnode data flags Bitcoin’s profit-taking metrics as a late bull market cycle signal. Bitcoin capital inflows have weakened, and large profit-taking has peaked since BTC hit $124,000, but a new all ...

AstraZeneca announced that the Phase III TULIP-SC trial of SAPHNELO (anifrolumab) for treatment of people with systemic lupus erythematosus met its primary endpoint. Trial results showed that ...